Pyrazole Derivatives Targeting CB2 Receptors for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain and inflammatory conditions, such as osteoarthritis and multiple sclerosis, often have limited efficacy and are associated with significant side effects, and there is a need for targeted therapies that modulate cannabinoid receptors to address various types of pain and inflammation without psychotropic effects.
Innovation Solution
Development of pyrazole derivatives that selectively modulate the CB2 receptor, which are administered in pharmaceutical compositions to treat pain, inflammation, and other conditions like multiple sclerosis, osteoarthritis, and autoimmune disorders, while minimizing effects on the CB1 receptor to avoid psychotropic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pain and inflammatory conditions are used, then therapeutic coverage is provided, but side effects are significant and efficacy is limited
Solution Approach 1:
The invention segments the cannabinoid receptor system by developing compounds that selectively target CB2 receptors while avoiding CB1 receptors. This segmentation allows therapeutic action on inflammatory pathways without activating psychotropic pathways, thereby improving efficacy while reducing side effects.
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (pyrazole derivatives with particular substituent patterns) that confer selective affinity for CB2 receptors. This local structural optimization enables the drug to interact preferentially with inflammatory pathways rather than central nervous system pathways.
2Reliability
If CB1 receptor activity is activated, then pain relief may be enhanced, but psychotropic effects occur
Solution Approach 1:
The invention extracts the desired analgesic and anti-inflammatory effects from the cannabinoid system by isolating CB2 receptor-mediated pathways. By developing selective CB2 modulators, the patent removes the unwanted psychotropic effects associated with CB1 activation while preserving therapeutic benefits.
Solution Approach 2:
The patent uses CB2-selective pyrazole derivatives as intermediaries to transmit therapeutic effects through inflammatory pathways without involving central nervous system pathways. These compounds act as selective mediators that bridge the gap between anti-inflammatory action and avoidance of psychotropic side effects.
Data Source
AI summary
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.